Use of tranexamic acid in melasma
Journal Title: Український журнал дерматології, венерології, косметології - Year 2019, Vol 0, Issue 3
Abstract
Tranexamic acid (TA) is an old drug used for a long time to treat or prevent excessive blood loss. In the beginning of the 1950s it was discovered that the amino acid lysine was able to inhibit activation of plasminogen, but the effect was too weak to be a candidate for the treatment of fibrinolytic haemorrhagic conditions. The first mention of TA in dermatology was in 1979 in actinic prurigo, with good results. Later it was demonstrated in vitro that TA was able to block melanogenesis. During the 2010’s more and more trials were published, assessing its efficacy in melasma, but also in erythrotelangiectasic rosacea. First, systemic TA was prescribed, but soon, because of the rare but severe complications susceptible of occurring, topical way was tested, giving similar results without risk of side effects. The particular interest of TA in the management of melasma is due to that it displays an activity at various levels. First, TA was shown to downregulate the activity of mast cells and consequently the release of histamine. Following the review of the currently available literature concerning the use of TA in melasma, it appears that this active ingredient permits achieving a good efficacy in this indication where there is no satisfactory therapy, with minor side effects. There are mainly three modalities of treatment of melasma with TA: oral administration and intradermal and topical applications. From the literature reviewed, it appears that the best results can be achieved by intradermal administration of TA (4 mg/l monthly) or topical 3 % TA (2/day). At this stage, the limitations of the currently available data are double: first, most of studies are concerning Asian skin, and secondly there is a lack of a large scale comparative study encompassing these three different ways of administration, which could confirm (or not) our analysis of currently published data.
Authors and Affiliations
C. Diehl
Keywords
Related Articles
- EP ID EP672779
- DOI 10.30978/UJDVK2019-3-104
- Views 101
- Downloads 0
Impact of clinical course of epidermolysis bullosis on quality of life of patients in Ukraine
Objective — to determine the impact of the severity of epidermolysis bullosa (EB) on the quality of life (QL) of patients with this disease. Materials and methods. The work was performed at the Department of Dermatology...
Dynamics of prooxidant and antioxidant homeostasis rates in patients with rosacea in the process of integrated treatment
Objective — to determine the dynamics of prooxidant and antioxidant homeostasis rates in patients with rosacea by using an antioxidant drug in their multimodality treatment. Materials and methods. The study involved 64...
Modern complex treatment of microsporia of the scalp in children
Objective — to increase the effectiveness of treatment of patients with microsporia of the scalp through the use of systemic antimycotics griseofulvin in combination with the original drug Аntral and antifungal agent 2 %...
Modern approaches to optimization of external therapy of pityriasis versicolor
According to different authors up to 10 % of the world population suffer from pityriasis versicolor. Considering the tendency to an increase in the incidence of this dermatosis, a change in the virulence of the pathogen,...
Dynamics of prooxidant and antioxidant homeostasis rates in patients with lichen ruber planus in the process of complex treatment
Objective — to determine and analyze the dynamics of the parameters of prooxidant antioxidant homeostasis and those of endogenous intoxication in patients with lichen ruber planus (LRP) when used in the complex treatment...